10x Genomics, Inc. reported its fourth quarter and full year 2025 financial results, including revenue of $166.0 million for Q4 2025 and $642.8 million for the full year, and provided 2026 revenue guidance of $600 million to $625 million. The company also announced strategic partnerships with the Cancer Research Institute, PharosAI, Dana-Farber Cancer Institute, and Brigham & Women's Hospital to advance cancer and autoimmune disease research.
Key takeaways
Q4 2025 revenue was $166.0 million, a 1% increase from Q4 2024 revenue of $165.0 million.
Full year 2025 revenue was $642.8 million, a 5% increase from 2024, but decreased 2% to $598.7 million when excluding $44.1 million of non-recurring patent litigation settlement revenue.
Full year 2025 net loss improved to $43.5 million from $182.6 million in 2024.
Cash and cash equivalents and marketable securities were $523.4 million as of December 31, 2025, an increase of $130.0 million over the prior year.
2026 revenue guidance is $600 million to $625 million, representing 0% to 4% growth over 2025 when excluding non-recurring revenue.
Announced partnerships with Cancer Research Institute and PharosAI to build AI-ready datasets for cancer research using Chromium and Xenium platforms.